trastuzumab
BioNTech and DualityBio Achieve Phase 3 Success with ADC Therapy for HER2-Positive Breast Cancer, Advancing Oncology Pipeline
BioNTech; DualityBio; antibody-drug conjugate (ADC); HER2-positive breast cancer; trastuzumab pamirtecan; BNT323/DB-1303; phase 3 trial; progression-free survival; oncology pipeline; ADC market
Enhertu Demonstrates Promising Efficacy in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases
Enhertu, Trastuzumab Deruxtecan, HER2-positive metastatic breast cancer, brain metastases, progression-free survival, objective response rate.
AstraZeneca and Daiichi Sankyo’s Enhertu Makes History in HER2-Ultralow Breast Cancer Treatment
Enhertu, AstraZeneca, Daiichi Sankyo, HER2-Ultralow Breast Cancer, ASCO, Metastatic Breast Cancer, Trastuzumab Deruxtecan, Antibody-Drug Conjugate (ADC), Breast Cancer Treatment